CD8A and neoplasm: TIL analysis demonstrated that ERY974 + cisplatin significantly increased the number of hCD3-, hCD4-, hCD8 and hCD45-positive cells in the tumour, and the number of GzmB/CD4, GzmB/CD8, PD-1/CD4 and PD-1/CD8-double-positive cells was higher in the combination group than that in the ERY974 monotherapy group (Supplementary Fig. 5b).